Intercept Pharmaceuticals to Present at Leerink Swann 2013 Global Healthcare
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver diseases, today announced that Mark Pruzanski, MD,
President and Chief Executive Officer, will present a company overview at the
Leerink Swann 2013 Global Healthcare Conference in New York on February 14,
2013 at 3:30 p.m. Eastern time.
The public may access Dr. Pruzanski's presentation live via webcast at
replay of the presentation will also be available and archived on Intercept's
website for two weeks.
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry. The company's
lead product candidate, obeticholic acid (OCA) is a bile acid analog and
first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially
being developed for the second line treatment of primary biliary cirrhosis
(PBC) in patients with an inadequate response to, or who are unable to
tolerate, ursodiol, the only approved therapy for this indication. OCA has
received orphan drug designation in both the United States and Europe for the
treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and
China, where it has out-licensed the product candidate to DSP. For more
information about Intercept, please visit the Company's website at:
For more information about Intercept, please contact Mark Pruzanski, M.D., or
Barbara Duncan, both of Intercept Pharmaceuticals, at 1-646-747-1000.
Press spacebar to pause and continue. Press esc to stop.